Novus Biologicals products are now on

Nur77 Activation and Tumor Suppression

Thu, 03/20/2014 - 14:31

Nur77 is a member of the steroid/thyroid hormone phosphoprotein receptor superfamily. It is heavily post-translationally modified and rapidly induced in response to androgens and growth factors. It governs fundamental processes such as cell proliferation, differentiation, and apoptosis. For some time, it was classified as an orphan receptor with no identifiable or known ligand, but scientists finally were able to identify a novel class of methylene-substituted diindolylmethanes (C-DIM) as its endogenous ligand. Researchers have used the NUR77 antibody to show that the activation of Nur77 in pancreatic, prostate, and breast cancer cells induces apoptosis1.

Immunohistochemistry-Paraffin: NUR77 Antibody Immunohistochemistry-Paraffin: NUR77 Antibody

Inamoto et al employed the NUR77 antibody to profile a wide variety of bladder cancer cell lines for Nur77 expression and cell death pathway signaling2. Their data suggest that Nur77 is a potent target for suppressing bladder tumors. The NUR77 antibody allowed Levin’s group to create detailed expression protein and phosphoprotein profiles using reverse-phase protein microarrays on serum-starved high-grade glioma and adenocarcinoma cell lines3. Mechanistic studies with the NUR77 antibody in pancreatic cancer cells found that activation of nuclear Nur77 triggers a novel pathway through cyclin-dependent kinase inhibitor p21 that requires both Sp1 and Sp4, but not Sp34. A molecular modeling study with the NUR77 antibody in paclitaxel-resistant cancer cells was performed to help researchers understand as well as guide future development of novel anticancer agents via targeting of the nontaxane skeleton shared between Nur77 and its mimetic paclitaxel5.

Novus Biologicals offers Nur77 reagents for your research needs including:


  1. 15871945
  2. 19074857
  3. 19894763
  4. 19584258
  5. 19671798

Blog Topics